vs
Side-by-side financial comparison of EGAIN Corp (EGAN) and Spero Therapeutics, Inc. (SPRO). Click either name above to swap in a different company.
EGAIN Corp is the larger business by last-quarter revenue ($23.0M vs $12.6M, roughly 1.8× Spero Therapeutics, Inc.). Spero Therapeutics, Inc. runs the higher net margin — 250.7% vs 10.2%, a 240.5% gap on every dollar of revenue. On growth, Spero Therapeutics, Inc. posted the faster year-over-year revenue change (24080.8% vs 2.6%). Over the past eight quarters, Spero Therapeutics, Inc.'s revenue compounded faster (847.7% CAGR vs 1.4%).
Headquartered in Sunnyvale, California, eGain Corporation helps businesses automate customer and employee experience with its AI knowledge software.
EGAN vs SPRO — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $23.0M | $12.6M |
| Net Profit | $2.3M | $31.5M |
| Gross Margin | 73.1% | — |
| Operating Margin | 8.9% | — |
| Net Margin | 10.2% | 250.7% |
| Revenue YoY | 2.6% | 24080.8% |
| Net Profit YoY | 248.1% | 250.9% |
| EPS (diluted) | $0.08 | $0.56 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $23.0M | $12.6M | ||
| Q3 25 | $23.5M | $0 | ||
| Q2 25 | $23.2M | $0 | ||
| Q1 25 | $21.0M | $12.0K | ||
| Q4 24 | $22.4M | $52.0K | ||
| Q3 24 | $21.8M | $65.0K | ||
| Q2 24 | $22.5M | $114.0K | ||
| Q1 24 | $22.4M | $140.0K |
| Q4 25 | $2.3M | $31.5M | ||
| Q3 25 | $2.8M | $-7.4M | ||
| Q2 25 | $30.9M | $-1.7M | ||
| Q1 25 | $66.0K | $-13.9M | ||
| Q4 24 | $671.0K | — | ||
| Q3 24 | $652.0K | $-17.1M | ||
| Q2 24 | $1.5M | $-17.9M | ||
| Q1 24 | $1.5M | $-12.7M |
| Q4 25 | 73.1% | — | ||
| Q3 25 | 75.2% | — | ||
| Q2 25 | 72.7% | — | ||
| Q1 25 | 68.0% | — | ||
| Q4 24 | 70.2% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.3% | — | ||
| Q1 24 | 69.3% | — |
| Q4 25 | 8.9% | — | ||
| Q3 25 | 12.1% | — | ||
| Q2 25 | 14.0% | — | ||
| Q1 25 | 0.1% | -122758.3% | ||
| Q4 24 | 2.9% | — | ||
| Q3 24 | 2.3% | -28604.6% | ||
| Q2 24 | 5.3% | -16720.2% | ||
| Q1 24 | 4.2% | -9987.1% |
| Q4 25 | 10.2% | 250.7% | ||
| Q3 25 | 12.0% | — | ||
| Q2 25 | 132.8% | — | ||
| Q1 25 | 0.3% | -115550.0% | ||
| Q4 24 | 3.0% | — | ||
| Q3 24 | 3.0% | -26380.0% | ||
| Q2 24 | 6.7% | -15668.4% | ||
| Q1 24 | 6.7% | -9049.3% |
| Q4 25 | $0.08 | $0.56 | ||
| Q3 25 | $0.10 | $-0.13 | ||
| Q2 25 | $1.09 | $-0.03 | ||
| Q1 25 | $0.00 | $-0.25 | ||
| Q4 24 | $0.02 | — | ||
| Q3 24 | $0.02 | $-0.32 | ||
| Q2 24 | $0.05 | $-0.33 | ||
| Q1 24 | $0.05 | $-0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $83.1M | $40.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.8M | $59.0M |
| Total Assets | $146.8M | $68.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $83.1M | $40.3M | ||
| Q3 25 | $70.9M | $48.6M | ||
| Q2 25 | $62.9M | $31.2M | ||
| Q1 25 | $68.7M | $48.9M | ||
| Q4 24 | $70.5M | $52.9M | ||
| Q3 24 | $67.2M | $76.3M | ||
| Q2 24 | $70.0M | $63.5M | ||
| Q1 24 | $83.0M | $82.3M |
| Q4 25 | $88.8M | $59.0M | ||
| Q3 25 | $83.5M | $26.5M | ||
| Q2 25 | $80.7M | $32.8M | ||
| Q1 25 | $51.6M | $33.8M | ||
| Q4 24 | $55.3M | $46.1M | ||
| Q3 24 | $55.7M | $65.5M | ||
| Q2 24 | $58.5M | $80.5M | ||
| Q1 24 | $63.9M | $96.2M |
| Q4 25 | $146.8M | $68.9M | ||
| Q3 25 | $144.6M | $54.2M | ||
| Q2 25 | $148.0M | $62.1M | ||
| Q1 25 | $106.2M | $77.7M | ||
| Q4 24 | $111.3M | $110.5M | ||
| Q3 24 | $114.9M | $135.2M | ||
| Q2 24 | $127.9M | $149.9M | ||
| Q1 24 | $120.3M | $167.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $10.1M | $-8.4M |
| Free Cash FlowOCF − Capex | $9.9M | — |
| FCF MarginFCF / Revenue | 43.0% | — |
| Capex IntensityCapex / Revenue | 1.0% | — |
| Cash ConversionOCF / Net Profit | 4.33× | -0.26× |
| TTM Free Cash FlowTrailing 4 quarters | $17.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $10.1M | $-8.4M | ||
| Q3 25 | $10.4M | $17.4M | ||
| Q2 25 | $-4.3M | $-17.7M | ||
| Q1 25 | $2.2M | $-4.0M | ||
| Q4 24 | $6.4M | $-23.4M | ||
| Q3 24 | $954.0K | $12.8M | ||
| Q2 24 | $-5.1M | $-18.7M | ||
| Q1 24 | $1.7M | $5.9M |
| Q4 25 | $9.9M | — | ||
| Q3 25 | $10.2M | — | ||
| Q2 25 | $-4.5M | — | ||
| Q1 25 | $2.1M | — | ||
| Q4 24 | $6.3M | — | ||
| Q3 24 | $845.0K | — | ||
| Q2 24 | $-5.2M | — | ||
| Q1 24 | $1.7M | — |
| Q4 25 | 43.0% | — | ||
| Q3 25 | 43.4% | — | ||
| Q2 25 | -19.5% | — | ||
| Q1 25 | 10.0% | — | ||
| Q4 24 | 28.1% | — | ||
| Q3 24 | 3.9% | — | ||
| Q2 24 | -23.0% | — | ||
| Q1 24 | 7.8% | — |
| Q4 25 | 1.0% | — | ||
| Q3 25 | 1.0% | — | ||
| Q2 25 | 0.9% | — | ||
| Q1 25 | 0.5% | — | ||
| Q4 24 | 0.6% | — | ||
| Q3 24 | 0.5% | — | ||
| Q2 24 | 0.2% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | 4.33× | -0.26× | ||
| Q3 25 | 3.70× | — | ||
| Q2 25 | -0.14× | — | ||
| Q1 25 | 33.48× | — | ||
| Q4 24 | 9.57× | — | ||
| Q3 24 | 1.46× | — | ||
| Q2 24 | -3.40× | — | ||
| Q1 24 | 1.17× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EGAN
| Transferred Over Time | $22.0M | 96% |
| Technology Service | $1.2M | 5% |
SPRO
Segment breakdown not available.
